{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T08:09:33Z","timestamp":1794125373080,"version":"4.8.0"},"reference-count":90,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"<jats:sec id=\"ab-srv220006-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) is the sixth most common malignancy and fourth leading cause of cancer-related death worldwide. Recent advances in systemic and locoregional therapies have led to changes in many guidelines regarding systemic therapy, as well as the possibility to downstage patients to undergo resection. This review examines the advances in surgical and medical therapies relative to multidisciplinary treatment strategies for HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-srv220006-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>HCC is a major health problem worldwide. The obesity epidemic has made nonalcoholic fatty liver disease a major risk factor for the development of HCC. Multiple societies, such as the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, the Asian Pacific Association for the Study of the Liver, and the National Comprehensive Cancer Network, provide guidelines for screening at-risk patients, as well as define staging systems to guide optimal treatment strategies. The Barcelona Clinic Liver Cancer staging system is widely accepted and has recently undergone updates with the introduction of new systemic therapies and stage migration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-srv220006-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The treatment of patients with HCC should involve a multidisciplinary approach with collaboration among surgeons, medical oncologists, radiation oncologists, and interventional radiologists to provide optimal care. Treatment paradigms must consider both tumor and patient-related factors such as extent of liver disease, which is a main driver of morbidity and mortality. The advent of more effective systemic and locoregional therapies has prolonged survival among patients with advanced disease and allowed some patients to undergo surgical intervention who would otherwise have disease considered unresectable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamasurg.2022.7989","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T11:03:09Z","timestamp":1676458989000},"page":"410","source":"Crossref","is-referenced-by-count":773,"title":["Management of Hepatocellular Carcinoma"],"prefix":"10.1001","volume":"158","author":[{"given":"Zachary J.","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamantis I.","family":"Tsilimigras","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha M.","family":"Ruff","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Mohseni","sequence":"additional","affiliation":[{"name":"Department of Radiology, John Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihab R.","family":"Kamel","sequence":"additional","affiliation":[{"name":"Department of Radiology, John Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Cloyd","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Ohio State University Wexner Medical Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"srv220006r1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.v68.6","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"srv220006r2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.","volume":"68","author":"Fujiwara","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"srv220006r3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"srv220006r4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.mayocpiqo.2019.04.005","article-title":"A practical guideline for hepatocellular carcinoma screening in patients at risk.","volume":"3","author":"Frenette","year":"2019","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"6","key":"srv220006r5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/ajg.2015.100","article-title":"Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis.","volume":"110","author":"Chang","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"srv220006r6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1158\/1055-9965.EPI-18-0281","article-title":"GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score.","volume":"28","author":"Yang","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"srv220006r7","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-022-00851-x","article-title":"Patient-, provider-, and system-level barriers to surveillance for hepatocellular carcinoma in high-risk patients in the US: a scoping review.","author":"Beal","year":"2022","journal-title":"J Gastrointest Cancer"},{"issue":"10","key":"srv220006r8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention, and management.","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"19","key":"srv220006r9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/jnci\/djp288","article-title":"Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.","volume":"101","author":"Chang","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"srv220006r10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/MEG.0000000000001152","article-title":"Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.","volume":"30","author":"Hassany","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"srv220006r11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1053\/j.gastro.2021.03.021","article-title":"Bariatric surgery reduces cancer risk in adults with nonalcoholic fatty liver disease and severe obesity.","volume":"161","author":"Rustgi","year":"2021","journal-title":"Gastroenterology"},{"issue":"20","key":"srv220006r12","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis.","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"issue":"22","key":"srv220006r13","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3748\/wjg.v24.i22.2348","article-title":"Noninvasive imaging of hepatocellular carcinoma: from diagnosis to prognosis.","volume":"24","author":"Jiang","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"2","key":"srv220006r14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/diagnostics11020323","article-title":"Clinical application of liver imaging reporting and data system for characterizing liver neoplasms: a meta-analysis.","volume":"11","author":"Li","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"8","key":"srv220006r15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices.","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"srv220006r16","first-page":"1","article-title":"Surgery and portal hypertension.","volume":"1","author":"Child","year":"1964","journal-title":"Major Probl Clin Surg"},{"issue":"4","key":"srv220006r17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1053\/he.2000.5852","article-title":"A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.","volume":"31","author":"Malinchoc","year":"2000","journal-title":"Hepatology"},{"issue":"6","key":"srv220006r18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/(ISSN)1527-6473","article-title":"Impact of Model for End-Stage Liver Disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis.","volume":"12","author":"Cucchetti","year":"2006","journal-title":"Liver Transpl"},{"issue":"6","key":"srv220006r19","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1245\/s10434-014-4099-2","article-title":"Survival benefit of liver transplantation vs resection for hepatocellular carcinoma: impact of MELD score.","volume":"22","author":"Vitale","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"srv220006r20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.amjsurg.2007.05.054","article-title":"Model for End-stage Liver Disease score fails to predict perioperative outcome after hepatic resection for hepatocellular carcinoma in patients without cirrhosis.","volume":"195","author":"Teh","year":"2008","journal-title":"Am J Surg"},{"issue":"6","key":"srv220006r21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach\u2014the ALBI grade.","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"srv220006r22","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/jgh.13250","article-title":"Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma.","volume":"31","author":"Hiraoka","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"srv220006r23","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.hpb.2021.11.003","article-title":"Liver stiffness-based model predicts hepatic venous pressure gradient in patients with liver disease.","volume":"24","author":"Rajakannu","year":"2022","journal-title":"HPB (Oxford)"},{"key":"srv220006r24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2147\/TCRM.S363849","article-title":"Indocyanine green retention test as a predictor of postoperative complications in patients with hepatitis B virus\u2013related hepatocellular carcinoma.","volume":"18","author":"Mai","year":"2022","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"srv220006r25","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E","article-title":"Natural history of hepatocellular carcinoma and prognosis in relation to treatment\u2014study of 850 patients.","volume":"56","author":"Okuda","year":"1985","journal-title":"Cancer"},{"issue":"3","key":"srv220006r26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s005350300038","article-title":"Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).","volume":"38","author":"Kudo","year":"2003","journal-title":"J Gastroenterol"},{"issue":"3","key":"srv220006r27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/hep.510280322","article-title":"A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.","volume":"28","year":"1998","journal-title":"Hepatology"},{"issue":"3","key":"srv220006r28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"12","key":"srv220006r29","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1245\/s10434-022-12242-4","article-title":"Critical analysis of the updated Barcelona Clinic Liver Cancer (BCLC) group guidelines.","volume":"29","author":"Tsilimigras","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"srv220006r30","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/SLA.0000000000002889","article-title":"Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma.","volume":"268","author":"Pinna","year":"2018","journal-title":"Ann Surg"},{"issue":"6","key":"srv220006r31","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.surg.2019.08.010","article-title":"Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: a multi-institutional analysis of 1010 patients.","volume":"166","author":"Tsilimigras","year":"2019","journal-title":"Surgery"},{"issue":"4","key":"srv220006r32","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jamcollsurg.2014.12.030","article-title":"Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified?","volume":"220","author":"Chapman","year":"2015","journal-title":"J Am Coll Surg"},{"issue":"9","key":"srv220006r33","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jamasurg.2016.1121","article-title":"Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma.","volume":"151","author":"Citterio","year":"2016","journal-title":"JAMA Surg"},{"issue":"4","key":"srv220006r34","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.surg.2017.06.006","article-title":"Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinoma.","volume":"162","author":"Rajakannu","year":"2017","journal-title":"Surgery"},{"issue":"2","key":"srv220006r35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.","volume":"69","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"srv220006r36","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/SLA.0000000000004346","article-title":"Overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the Milan criteria.","volume":"272","author":"Tsilimigras","year":"2020","journal-title":"Ann Surg"},{"issue":"7","key":"srv220006r37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ejso.2018.04.018","article-title":"Anatomic versus nonanatomic resection for hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"44","author":"Moris","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"srv220006r38","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s11605-018-4016-2","article-title":"Early morbidity and mortality after minimally invasive liver resection for hepatocellular carcinoma: a propensity score\u2013matched comparison with open resection.","volume":"23","author":"Xourafas","year":"2019","journal-title":"J Gastrointest Surg"},{"issue":"11","key":"srv220006r39","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"srv220006r40","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1002\/lt.22365","article-title":"Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience.","volume":"17","author":"Mazzaferro","year":"2011","journal-title":"Liver Transpl"},{"issue":"2","key":"srv220006r41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jhep.2019.11.017","article-title":"Advances in resection and transplantation for hepatocellular carcinoma.","volume":"72","author":"Vibert","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"srv220006r42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"issue":"6","key":"srv220006r43","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.","volume":"61","author":"Yao","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"srv220006r44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrclinonc.2014.237","article-title":"Image-guided ablation of primary liver and renal tumours.","volume":"12","author":"Breen","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"srv220006r45","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/gutjnl-2016-312629","article-title":"Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial.","volume":"66","author":"Yu","year":"2017","journal-title":"Gut"},{"issue":"4","key":"srv220006r46","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","article-title":"A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma.","volume":"57","author":"Feng","year":"2012","journal-title":"J Hepatol"},{"issue":"2","key":"srv220006r47","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jhep.2013.04.009","article-title":"Cost-effectiveness of hepatic resection vs percutaneous radiofrequency ablation for early hepatocellular carcinoma.","volume":"59","author":"Cucchetti","year":"2013","journal-title":"J Hepatol"},{"issue":"6","key":"srv220006r48","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/SLA.0b013e3181efc656","article-title":"A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.","volume":"252","author":"Huang","year":"2010","journal-title":"Ann Surg"},{"issue":"9","key":"srv220006r49","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jvir.2022.05.019","article-title":"Microwave ablation as bridging to liver transplant for patients with hepatocellular carcinoma: a single-center retrospective analysis.","volume":"33","author":"Couillard","year":"2022","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"srv220006r50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0305-7372(88)90024-2","article-title":"Regional chemotherapy of liver metastases from colorectal carcinoma: hepatic artery or portal vein infusion?","volume":"15","author":"Chu","year":"1988","journal-title":"Cancer Treat Rev"},{"issue":"9 Pt 2","key":"srv220006r51","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1016\/S1051-0443(07)61789-8","article-title":"Chemoembolization of hepatocellular carcinoma.","volume":"13","author":"Ramsey","year":"2002","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"srv220006r52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"srv220006r53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"srv220006r54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised vs standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"srv220006r55","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil vs sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1).","volume":"40","author":"Lyu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"srv220006r56","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial.","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"srv220006r57","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial.","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"srv220006r58","article-title":"Hepatic arterial infusion chemotherapy vs transarterial chemoembolization in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"40","author":"Beran","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"srv220006r59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline.","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"srv220006r60","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.radonc.2019.12.004","article-title":"Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review.","volume":"145","author":"Lee","year":"2020","journal-title":"Radiother Oncol"},{"issue":"6","key":"srv220006r61","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1002\/hep.30591","article-title":"Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis.","volume":"69","author":"Hara","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"srv220006r62","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial.","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"issue":"7","key":"srv220006r63","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/jso.22104","article-title":"Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response.","volume":"105","author":"Facciuto","year":"2012","journal-title":"J Surg Oncol"},{"issue":"12","key":"srv220006r64","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4240\/wjgs.v9.i12.256","article-title":"Hepatocellular carcinoma with child Pugh-A cirrhosis treated with stereotactic body radiotherapy.","volume":"9","author":"Hasan","year":"2017","journal-title":"World J Gastrointest Surg"},{"issue":"24","key":"srv220006r65","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.18.02184","article-title":"Neoadjuvant 3-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study.","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"srv220006r66","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"10126","key":"srv220006r67","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferiority trial.","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"srv220006r68","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"12","key":"srv220006r69","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1078-0432.CCR-21-3807","article-title":"Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: data from the open-label, phase 2 KEYNOTE-224 trial.","volume":"28","author":"Verset","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"srv220006r70","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10064","key":"srv220006r71","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for Patients With Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"srv220006r72","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"srv220006r73","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab After Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Increased a-Fetoprotein Concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"srv220006r74","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: the CheckMate 040 randomized clinical trial.","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"srv220006r75","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: a randomized, double-blind, phase 3 trial.","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10088","key":"srv220006r76","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): an open-label, noncomparative, phase 1\/2 dose escalation and expansion trial.","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"srv220006r77","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1200\/JCO.2021.39.3_suppl.9","article-title":"Safety and efficacy of anti\u2013PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study.","volume":"39","author":"Andre","year":"2021","journal-title":"J Clin Oncol"},{"issue":"20","key":"srv220006r78","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"srv220006r79","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","article-title":"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7593","key":"srv220006r80","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"issue":"1","key":"srv220006r81","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.gastro.2020.09.031","article-title":"Steatohepatitis impairs T-cell\u2013directed immunotherapies against liver tumors in mice.","volume":"160","author":"Heinrich","year":"2021","journal-title":"Gastroenterology"},{"key":"srv220006r82","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1200\/JCO.2022.40.4_suppl.470","article-title":"IMbrave150: exploratory efficacy and safety in patients with  unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study.","volume":"40","author":"Toh","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"srv220006r83","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00262-018-2190-4","article-title":"Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.","volume":"67","author":"Brown","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"srv220006r84","doi-asserted-by":"crossref","first-page":"TPS57","DOI":"10.1200\/JCO.2019.37.8_suppl.TPS57","article-title":"Phase I\/II trial of BMS-986205 and nivolumab as first-line therapy in hepatocellular carcinoma.","volume":"37","author":"Chen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"srv220006r85","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1634\/theoncologist.2016-0094","article-title":"Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization\u201410 years of experience.","volume":"21","author":"Zhang","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"srv220006r86","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"srv220006r87","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity.","volume":"2","author":"Ho","year":"2021","journal-title":"Nat Cancer"},{"issue":"13","key":"srv220006r88","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"srv220006r90","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/cld.879","article-title":"Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma.","volume":"15","author":"Huppert","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"srv220006r89","unstructured":"A study of atezolizumab plus bevacizumab vs active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation (IMbrave050). ClinicalTrials.gov identifier: NCT04102098. Updated November 21, 2022. Accessed November 1, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04102098"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2801509\/jamasurgery_brown_2023_rv_220006_1680632769.1003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T11:10:57Z","timestamp":1681297857000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2801509"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2022.7989","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,1]]}}}